Competitive Inhibition of Renal Tubular Secretion of Gemifloxacin by Probenecid∇

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3902-3907

  Landersdorfer, Cornelia B ^a,d   Kirkpatrick, Carl M J ^b   Kinzig, Martina ^a   Bulitta, Jürgen B ^a,d   Holzgrabe, Ulrike ^c   Drusano, George L ^d   Sörgel, Fritz ^a,e  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d ORDWAY RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GEMIFLOXACIN; PROBENECID;

ADULT; ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG URINE LEVEL; FEMALE; HUMAN; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, PHARMACEUTIC; FEMALE; FLUOROQUINOLONES; HUMANS; KIDNEY FUNCTION TESTS; KIDNEY TUBULES; MALE; METABOLIC CLEARANCE RATE; NAPHTHYRIDINES; PROBENECID;

EID: 70349086126     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01200-08     Document Type: Article

References (35)

1. Allen, A., N. Bird, R. Dixon, F. Hickmott, V. Pay, A. Smith, and M. Stahl. 2001. Effect of cimetidine on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Clin. Drug Investig. 21:519-526.
2. Allen, A., E. Bygate, S. Oliver, M. Johnson, C. Ward, A.-J. Cheon, Y. S. Choo, and I.-C. Kim. 2000. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 44:1604-1608.
3. Anonymous. 1999. FACTIVE investigator brochure, 4th ed. SmithKline-Beecham, Herts, United Kingdom.
4. Beal, S. L., A. J. Boeckmann, L. B. Sheiner, and the NONMEM Project Group. 1999. NONMEM users guides, version 5. University of California at San Francisco, San Francisco.
5. Bulitta, J. B., S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sörgel. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51:2497-2507.
6. Clinckers, R., I. Smolders, A. Meurs, G. Ebinger, and Y. Michotte. 2005. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J. Pharmacol. Exp. Ther. 314:725-731.
7. Cormican, M. G., and R. N. Jones. 1997. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. 41:204-211.
8. Cummins, C. L., C. Y. Wu, and L. Z. Benet. 2002. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 72:474-489.
9. Emanuelsson, B. M., B. Beermann, and L. K. Paalzow. 1987. Non-linear elimination and protein binding of probenecid. Eur. J. Clin. Pharmacol. 32:395-401.
10. Fish, D. N., and A. T. Chow. 1997. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32:101-119.
11. Gaitonde, M. D., P. Mendes, E. S. A. House, and K. H. Lehr. 1995. The effects of cimetidine and probenecid on the pharmacokinetics of levofloxacin (LVFX), abstr. A41, p. 8. Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
12. Garton, A. M., R. P. Rennie, J. Gilpin, M. Marrelli, and S. D. Shafran. 1997. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels. J. Antimicrob. Chemother. 40:903-906.
13. Gisclon, L. G., R. A. Boyd, R. L. Williams, and K. M. Giacomini. 1989. The effect of probenecid on the renal elimination of cimetidine. Clin. Pharmacol. Ther. 45:444-452.
14. Jaehde, U., F. Sorgel, A. Reiter, G. Sigl, K. G. Naber, and W. Schunack. 1995. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin. Pharmacol. Ther. 58:532-541.
15. Kamali, F. 1993. The effect of probenecid on paracetamol metabolism and pharmacokinetics. Eur. J. Clin. Pharmacol. 45:551-553.
16. Kamali, F., and M. D. Rawlins. 1992. Influence of probenecid and paracetamol (acetaminophen) on zidovudine glucuronidation in human liver in vitro. Biopharm. Drug Dispos. 13:403-409.
17. Kim, K. A., S. O. Oh, P. W. Park, and J. Y. Park. 2005. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur. J. Clin. Pharmacol. 61:275-280.
18. Landersdorfer, C. B., C. M. Kirkpatrick, M. Kinzig-Schippers, J. B. Bulitta, U. Holzgrabe, G. L. Drusano, and F. Sörgel. 2007. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob. Agents Chemother. 51:3290-3297.
19. Landersdorfer, C. B., C. M. Kirkpatrick, M. Kinzig, J. B. Bulitta, U. Holzgrabe, and F. Sorgel. 2008. Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br. J. Clin. Pharmacol. 66:648-659.
20. Meier, P. J., U. Eckhardt, A. Schroeder, B. Hagenbuch, and B. Stieger. 1997. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667-1677.
21. Nakashima, M., T. Uematsu, K. Kosuge, H. Kusajima, T. Ooie, Y. Masuda, R. Ishida, and H. Uchida. 1995. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:2635-2640.
22. Okuda, M., N. Kimura, and K. Inui. 2006. Interactions of fluoroquinolone antibacterials, DX-619 and levofloxacin, with creatinine transport by renal organic cation transporter hOCT2. Drug Metab. Pharmacokinet. 21:432-436.
23. Shiba, K., A. Saito, J. Shimada, S. Hori, M. Kaji, T. Miyahara, H. Kusajima, S. Kaneko, S. Saito, T. Ooie, and H. Uchida. 1990. Renal handling of fleroxacin in rabbits, dogs, and humans. Antimicrob. Agents Chemother. 34:58-64.
24. Shimada, J., T. Nogita, and Y. Ishibashi. 1993. Clinical pharmacokinetics of sparfloxacin. Clin. Pharmacokinet. 25:358-369.
25. Shimada, J., T. Yamaji, Y. Ueda, H. Uchida, H. Kusajima, and T. Irikura. 1983. Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrob. Agents Chemother. 23:1-7.
26. Shitara, Y., H. Sato, and Y. Sugiyama. 2005. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45:689-723.
27. Sorgel, F., J. Bulitta, and M. Kinzig-Schippers. 2001. How well do gyrase inhibitors work? The pharmacokinetics of quinolones. Pharm. Unserer Zeit 30:418-427.
28. Stass, H., and R. Sachse. 2001. Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers. Clin. Pharmacokinet. 40(Suppl. 1):71-76.
29. Sweet, D. H., L. M. Chan, R. Walden, X. P. Yang, D. S. Miller, and J. B. Pritchard. 2003. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am. J. Physiol. Renal Physiol. 284:F763-F769.
30. Sweet, D. H., N. A. Wolff, and J. B. Pritchard. 1997. Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J. Biol. Chem. 272:30088-30095.
31. Ullrich, K. J., G. Rumrich, C. David, and G. Fritzsch. 1993. Bisubstrates: substances that interact with both, renal contraluminal organic anion and organic cation transport systems. II. Zwitterionic substrates: dipeptides, cephalosporins, quinolone-carboxylate gyrase inhibitors and phosphamide thiazine carboxylates; nonionizable substrates: steroid hormones and cyclophosphamides. Pflugers Arch. 425:300-312.
32. VanWert, A. L., C. Srimaroeng, and D. H. Sweet. 2008. Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol. Pharmacol. 74:122-131.
33. Vlasses, P. H., A. M. Holbrook, J. J. Schrogie, J. D. Rogers, R. K. Ferguson, and W. B. Abrams. 1980. Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. Antimicrob. Agents Chemother. 17:847-855.
34. Vree, T. B., E. W. Van Ewijk-Beneken Kolmer, E. W. Wuis, and Y. A. Hekster. 1992. Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. Pharm. Weekbl. Sci. 14:325-331.
35. Wijnands, W. J., T. B. Vree, A. M. Baars, and C. L. van Herwaarden. 1988. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. J. Antimicrob. Chemother. 21(Suppl. B):67-77.